Antisense modulation of glycogen synthase kinase 3 beta expression
AssigneeIsis Pharmaceuticals, Inc.
InventorsMadeline M. Butler, Robert McKay, Brett P. Monia, Jacqueline Wyatt
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.
Claims26
An antisense compound 8 to 30 nucleobases in length targeted to nucleotides 21 through 46 or nucleotides 57 through 70 of a 5′ untranslated region of human glycogen synthase kinase 3 beta (SEQ ID NO:10), nucleotides 60 through 142, nucleotides 154 through 173, nucleotides 224 through 269, nucleotides 294 through 313, nucleotides 326 through 385, nucleotides 396 through 423, nucleotides 428 through 470, nucleotides 509 through 528, nucleotides 535 through 583, nucleotides 592 through 658, nucleotides 676 through 725, nucleotides 745 through 767, nucleotides 783 through 812, nucleotides 820 through 839, nucleotides 874 through 899, nucleotides 963 through 982, nucleotides 1002 through 1145, nucleotides 1155 through 1203, nucleotides 1244 through 1291 of a coding region, nucleotides 1292 through 1311 of a stop codon, or nucleotides 1327 through 1383 of a 3′ untranslated region of human glycogen synthase kinase 3 beta (SEQ ID NO:3), wherein said antisense compound specifically hybridizes with and inhibits the expression of human glycogen synthase kinase 3 beta.
An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84 or 85 which inhibits the expression of human glycogen synthase kinase 3 beta.
Dependencies are inferred from the claim text.